TY - JOUR
T1 - Usefulness of circulating tumor DNA by targeting human papilloma virus-derived sequences as a biomarker in p16-positive oropharyngeal cancer
AU - Akashi, Ken
AU - Sakai, Toshihiko
AU - Fukuoka, Osamu
AU - Saito, Yuki
AU - Yoshida, Masafumi
AU - Ando, Mizuo
AU - Ito, Takeshi
AU - Murakami, Yoshinori
AU - Yamasoba, Tatsuya
N1 - Funding Information:
The authors would like to thank the members of the Department of Otolaryngology and Head and Neck Surgery, Graduate School of Medicine, University of Tokyo Hospital and the Division of Molecular Pathology, Institute of Medical Science, University of Tokyo for their constructive criticism and fruitful discussion. The authors also thank Enago (http://www.enago.jp) for the English language review. This work was supported in part by JSPS KAKENHI Grant Numbers JP16H06759 and JP18K16833.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - In head and neck cancer, early detection of recurrence after treatment is important. The contemporary development of therapeutic agents have improved the prognosis after recurrence; however, no biomarker has been established for evaluating therapeutic effects or detecting recurrence. Recently, circulating tumor DNA (ctDNA), which comprises DNA derived from tumor cells and exists in the form of cell-free DNA in the blood, has attracted attention as a minimally invasive and repeatable biomarker for detecting cancer. We validated the usefulness of ctDNA of human papilloma virus (HPV)-derived sequences as a biomarker in HPV-related p16-positive oropharyngeal cancer by assessing 25 patients with p16-positive oropharyngeal cancer. Blood samples were collected from each patient at multiple time points during the treatment, and the plasma was preserved. The ctDNA was extracted from the plasma and analyzed using digital polymerase chain reaction. HPV-derived ctDNA was detected in 14 (56%) of the 25 patients. In all the patients, the samples were found to be ctDNA-negative after initial treatment. Cancer recurrence was observed in 2 of the 14 patients; HPV-derived ctDNA was detected at the time of recurrence. Our results indicate that HPV-derived ctDNA can be a prospective biomarker for predicting the recurrence of p16-positive oropharyngeal cancer.
AB - In head and neck cancer, early detection of recurrence after treatment is important. The contemporary development of therapeutic agents have improved the prognosis after recurrence; however, no biomarker has been established for evaluating therapeutic effects or detecting recurrence. Recently, circulating tumor DNA (ctDNA), which comprises DNA derived from tumor cells and exists in the form of cell-free DNA in the blood, has attracted attention as a minimally invasive and repeatable biomarker for detecting cancer. We validated the usefulness of ctDNA of human papilloma virus (HPV)-derived sequences as a biomarker in HPV-related p16-positive oropharyngeal cancer by assessing 25 patients with p16-positive oropharyngeal cancer. Blood samples were collected from each patient at multiple time points during the treatment, and the plasma was preserved. The ctDNA was extracted from the plasma and analyzed using digital polymerase chain reaction. HPV-derived ctDNA was detected in 14 (56%) of the 25 patients. In all the patients, the samples were found to be ctDNA-negative after initial treatment. Cancer recurrence was observed in 2 of the 14 patients; HPV-derived ctDNA was detected at the time of recurrence. Our results indicate that HPV-derived ctDNA can be a prospective biomarker for predicting the recurrence of p16-positive oropharyngeal cancer.
UR - http://www.scopus.com/inward/record.url?scp=85122838413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122838413&partnerID=8YFLogxK
U2 - 10.1038/s41598-021-04307-3
DO - 10.1038/s41598-021-04307-3
M3 - Article
C2 - 35022425
AN - SCOPUS:85122838413
VL - 12
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 572
ER -
